Mainz Biomed announces a follow-on offering of 2.2 million units, aiming for $3 million in gross proceeds.
Quiver AI Summary
Mainz Biomed N.V. announced a follow-on offering of 2,222,222 units, priced at $1.35 each, aiming to raise approximately $3.0 million. Each unit comprises one ordinary share and a Series A warrant allowing the purchase of one and a half ordinary shares at the same price, with the warrants exercisable immediately and expiring in five years. The offering is managed by Maxim Group LLC and is expected to close around August 5, 2025, pending customary conditions. This issuance is registered under a recently effective registration statement with the SEC. Mainz Biomed specializes in molecular genetic diagnostics, including their flagship colorectal cancer test, ColoAlert®, and is working toward FDA approval for its products.
Potential Positives
- Mainz Biomed announced a follow-on offering of 2,222,222 units, raising approximately $3.0 million, which can be utilized to fund ongoing and future projects, including regulatory approvals and clinical studies.
- The pricing of the units at $1.35 per share is positioned to attract potential investors, providing liquidity and enhancing the company’s capital structure.
- The offering includes Series A warrants that are immediately exercisable, allowing investors to increase their stake in the company and demonstrating confidence in Mainz Biomed’s growth potential.
- The planned use of funds for the pivotal FDA clinical study underscores the company’s commitment to advancing its product candidates towards market readiness, particularly for impactful diagnostic solutions like ColoAlert® and PancAlert.
Potential Negatives
- The follow-on offering of $3.0 million suggests potential cash flow issues, possibly indicating a need for additional funding to support ongoing operations and development.
- The priced offering at $1.35 per unit may reflect a decrease in investor confidence, as it could be perceived as undervaluing the company's shares compared to previous valuations.
- The press release mentions several risks and uncertainties that could lead to actual results differing materially from the company's expectations, which may raise concerns among investors about the company's stability and future prospects.
FAQ
What is Mainz Biomed's recent follow-on offering?
Mainz Biomed has announced a follow-on offering of 2,222,222 units for gross proceeds of approximately $3.0 million.
What is included in each unit of the offering?
Each unit consists of one ordinary share (or pre-funded warrant) and one Series A warrant to purchase one and one half ordinary shares.
When is the expected closing date for the offering?
The offering is expected to close on or about August 5, 2025, subject to customary closing conditions.
How can investors obtain the final prospectus for the offering?
Investors can obtain copies of the final prospectus from Maxim Group LLC at their New York office or by contacting them directly.
What products does Mainz Biomed offer?
Mainz Biomed specializes in molecular genetic diagnostic solutions, including ColoAlert® for colorectal cancer and PancAlert for pancreatic cancer screening.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYNZ Analyst Ratings
Wall Street analysts have issued reports on $MYNZ in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 02/14/2025
To track analyst ratings and price targets for $MYNZ, check out Quiver Quantitative's $MYNZ forecast page.
Full Release
BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,222,222 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof) and one Series A warrant to purchase one and one half ordinary shares for gross proceeds of approximately $3.0 million. Each unit is being sold at an effective offering price of $1.35 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance.
Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about August 5, 2025, subject to customary closing conditions.
The newly issued securities described above are being offered pursuant to a registration statement on Form F-1, as amended (File No. 333-289095) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on August 4, 2025. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
[email protected]
For investor inquiries, please contact [email protected]
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
